BusinessAxsome Therapeutics to Present at the Ladenburg Thalmann 2016 Healthcare ConferenceBy Nasdaq OMXSep 19, 2016, 11:00 AM UTC
BusinessAxsome Therapeutics Reports Second Quarter 2016 Financial ResultsBy Nasdaq OMXAug 9, 2016, 9:30 PM UTC
BusinessAxsome Therapeutics Receives Pre-IND Guidance from FDA for AXS-05 for Agitation in Patients with Alzheimer’s DiseaseBy Nasdaq OMXApr 20, 2016, 11:00 AM UTC
BusinessAxsome Therapeutics to Present at the 15th Annual Needham Healthcare ConferenceBy Nasdaq OMXApr 4, 2016, 11:00 AM UTC
BusinessAxsome Therapeutics Initiates Phase 3 Study of AXS-02 for Knee Osteoarthritis Associated with Bone Marrow LesionsBy Nasdaq OMXMar 28, 2016, 11:00 AM UTC
